Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005811 · ClinicalTrials.gov registry record · Phase 2
Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00005811: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00005811 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005811, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well topotecan hydrochloride works in treating children with meningeal cancer that has not responded to previous treatment
Interventions
- OTHER laboratory biomarker analysis
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2000-04 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005811
The ClinicalTrials.gov registry entry for NCT00005811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00005811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005811 about?
NCT00005811 is a clinical study titled "Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment". Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well topotecan hydrochloride works in treating children with meningeal cancer that has not responded to previous treatment
What is the current status of trial NCT00005811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2000-04. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00005811?
The interventions under investigation include: laboratory biomarker analysis (OTHER), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005811?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.